Late relapses in acute myeloid leukemia: Analysis of characteristics and outcome

Dushyant Verma, Hagop Kantarjian, Stefan Faderl, Susan O'Brien, Sherry Pierce, Khanh Vu, Emil Freireich, Michael Keating, Jorge Cortes, Farhad Ravandi

Research output: Contribution to journalArticle

Abstract

Relapse after 5 years of complete remission (CR) is uncommon in acute myeloid leukemia (AML). Among 2347 patients seen between 1980 and 2008, 1366 achieved CR; 942 relapsed. Eleven (1.16 of all relapses) relapsed after a CR of>5 years. The median age was 66 years (range, 3779). Initial therapy was cytarabine plus anthracycline in six, amsacrine-based in three, and other in two. The median CR1 duration was 81 months (range, 60137). At relapse, the karyotype was different from the initial finding in five of eight (63) patients with available data. Treatment for relapse included cytarabine with anthracycline in eight, and other in three patients, with a second CR (CR2) achieved in four (36). The median CR2 duration was 1 month (range, 037), and median survival after relapse was 6.4 months (range, 139). Late relapses in AML are infrequent, with poor response to therapy. Karyotype at relapse is frequently different, raising the question of second AML versus relapse with the original clone.

Original languageEnglish (US)
Pages (from-to)778-782
Number of pages5
JournalLeukemia and Lymphoma
Volume51
Issue number5
DOIs
StatePublished - May 1 2010
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Recurrence
Anthracyclines
Cytarabine
Karyotype
Amsacrine
Therapeutics
Clone Cells
Survival

Keywords

  • Acute myeloid leukemia
  • AML
  • Late relapse

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Verma, D., Kantarjian, H., Faderl, S., O'Brien, S., Pierce, S., Vu, K., ... Ravandi, F. (2010). Late relapses in acute myeloid leukemia: Analysis of characteristics and outcome. Leukemia and Lymphoma, 51(5), 778-782. https://doi.org/10.3109/10428191003661852

Late relapses in acute myeloid leukemia : Analysis of characteristics and outcome. / Verma, Dushyant; Kantarjian, Hagop; Faderl, Stefan; O'Brien, Susan; Pierce, Sherry; Vu, Khanh; Freireich, Emil; Keating, Michael; Cortes, Jorge; Ravandi, Farhad.

In: Leukemia and Lymphoma, Vol. 51, No. 5, 01.05.2010, p. 778-782.

Research output: Contribution to journalArticle

Verma, D, Kantarjian, H, Faderl, S, O'Brien, S, Pierce, S, Vu, K, Freireich, E, Keating, M, Cortes, J & Ravandi, F 2010, 'Late relapses in acute myeloid leukemia: Analysis of characteristics and outcome', Leukemia and Lymphoma, vol. 51, no. 5, pp. 778-782. https://doi.org/10.3109/10428191003661852
Verma D, Kantarjian H, Faderl S, O'Brien S, Pierce S, Vu K et al. Late relapses in acute myeloid leukemia: Analysis of characteristics and outcome. Leukemia and Lymphoma. 2010 May 1;51(5):778-782. https://doi.org/10.3109/10428191003661852
Verma, Dushyant ; Kantarjian, Hagop ; Faderl, Stefan ; O'Brien, Susan ; Pierce, Sherry ; Vu, Khanh ; Freireich, Emil ; Keating, Michael ; Cortes, Jorge ; Ravandi, Farhad. / Late relapses in acute myeloid leukemia : Analysis of characteristics and outcome. In: Leukemia and Lymphoma. 2010 ; Vol. 51, No. 5. pp. 778-782.
@article{a63b76a2223e48e7a6c2cc37d583e736,
title = "Late relapses in acute myeloid leukemia: Analysis of characteristics and outcome",
abstract = "Relapse after 5 years of complete remission (CR) is uncommon in acute myeloid leukemia (AML). Among 2347 patients seen between 1980 and 2008, 1366 achieved CR; 942 relapsed. Eleven (1.16 of all relapses) relapsed after a CR of>5 years. The median age was 66 years (range, 3779). Initial therapy was cytarabine plus anthracycline in six, amsacrine-based in three, and other in two. The median CR1 duration was 81 months (range, 60137). At relapse, the karyotype was different from the initial finding in five of eight (63) patients with available data. Treatment for relapse included cytarabine with anthracycline in eight, and other in three patients, with a second CR (CR2) achieved in four (36). The median CR2 duration was 1 month (range, 037), and median survival after relapse was 6.4 months (range, 139). Late relapses in AML are infrequent, with poor response to therapy. Karyotype at relapse is frequently different, raising the question of second AML versus relapse with the original clone.",
keywords = "Acute myeloid leukemia, AML, Late relapse",
author = "Dushyant Verma and Hagop Kantarjian and Stefan Faderl and Susan O'Brien and Sherry Pierce and Khanh Vu and Emil Freireich and Michael Keating and Jorge Cortes and Farhad Ravandi",
year = "2010",
month = "5",
day = "1",
doi = "10.3109/10428191003661852",
language = "English (US)",
volume = "51",
pages = "778--782",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Late relapses in acute myeloid leukemia

T2 - Analysis of characteristics and outcome

AU - Verma, Dushyant

AU - Kantarjian, Hagop

AU - Faderl, Stefan

AU - O'Brien, Susan

AU - Pierce, Sherry

AU - Vu, Khanh

AU - Freireich, Emil

AU - Keating, Michael

AU - Cortes, Jorge

AU - Ravandi, Farhad

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Relapse after 5 years of complete remission (CR) is uncommon in acute myeloid leukemia (AML). Among 2347 patients seen between 1980 and 2008, 1366 achieved CR; 942 relapsed. Eleven (1.16 of all relapses) relapsed after a CR of>5 years. The median age was 66 years (range, 3779). Initial therapy was cytarabine plus anthracycline in six, amsacrine-based in three, and other in two. The median CR1 duration was 81 months (range, 60137). At relapse, the karyotype was different from the initial finding in five of eight (63) patients with available data. Treatment for relapse included cytarabine with anthracycline in eight, and other in three patients, with a second CR (CR2) achieved in four (36). The median CR2 duration was 1 month (range, 037), and median survival after relapse was 6.4 months (range, 139). Late relapses in AML are infrequent, with poor response to therapy. Karyotype at relapse is frequently different, raising the question of second AML versus relapse with the original clone.

AB - Relapse after 5 years of complete remission (CR) is uncommon in acute myeloid leukemia (AML). Among 2347 patients seen between 1980 and 2008, 1366 achieved CR; 942 relapsed. Eleven (1.16 of all relapses) relapsed after a CR of>5 years. The median age was 66 years (range, 3779). Initial therapy was cytarabine plus anthracycline in six, amsacrine-based in three, and other in two. The median CR1 duration was 81 months (range, 60137). At relapse, the karyotype was different from the initial finding in five of eight (63) patients with available data. Treatment for relapse included cytarabine with anthracycline in eight, and other in three patients, with a second CR (CR2) achieved in four (36). The median CR2 duration was 1 month (range, 037), and median survival after relapse was 6.4 months (range, 139). Late relapses in AML are infrequent, with poor response to therapy. Karyotype at relapse is frequently different, raising the question of second AML versus relapse with the original clone.

KW - Acute myeloid leukemia

KW - AML

KW - Late relapse

UR - http://www.scopus.com/inward/record.url?scp=77951864626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951864626&partnerID=8YFLogxK

U2 - 10.3109/10428191003661852

DO - 10.3109/10428191003661852

M3 - Article

C2 - 20196624

AN - SCOPUS:77951864626

VL - 51

SP - 778

EP - 782

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5

ER -